Profile
ATXI NVO REGN VRTX MRNA SGEN
Company Name Avenue Therapeutics, Inc. Novo Nordisk A/S Regeneron Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated Moderna, Inc. Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $2.87M $566.57B $103.71B $103.60B $47.86B $43.15B
Employees 0.00K 63.37K 13.45K 5.40K 5.60K 3.26K
CEO Dr. Alexandra MacLean M.D. Mr. Lars Fruergaard Jorgensen Dr. Leonard S. Schleifer M.D., Ph.D. Dr. Reshma Kewalramani FASN, M.D. Mr. Stephane Bancel Mr. David R. Epstein B.Sc., M.B.A.
Ratings
Trading
ATXI NVO REGN VRTX MRNA SGEN
Last Close $4.78 $123.05 $957 $401.08 $125 $228.74
High 52 $6.2 $199.54 $993.35 $446.08 $137.75 $228.9
Low 52 $0.09 $87.78 $692.45 $323.57 $69.51 $187.64
Price vs. 52 Week High -22.9 % -38.33 % -3.66 % -10.09 % -9.26 % -0.07 %
Price vs. 52 Week Low 5211.11 % 40.18 % 38.2 % 23.95 % 79.83 % 21.9 %
Total Return
ATXI NVO REGN VRTX MRNA SGEN
1 Month Return 3151.7 % -0.73 % 2.13 % -0.73 % 22.23 % 0 %
3 Month Return 3309.42 % 8.22 % 1.25 % -5.56 % 28.21 % 0 %
6 Month Return 1810.47 % 25.34 % 17.15 % 6.61 % 61.23 % 6.39 %
9 Month Return 359.62 % -21.42 % 24.86 % 17.8 % 15.54 % 18.23 %
YTD Return 2868.94 % 18.95 % 8.96 % -1.43 % 25.69 % 0 %
1 Year Return 367.3 % -23.3 % 26.94 % 15.72 % -6.95 % 15.23 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ATXI NVO REGN VRTX MRNA SGEN
Dividend Yield Percentage (TTM) - 0.16 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.1 % 6.2 % 13.69 % -3.65 % -3.35 %
Dividend Per Share (TTM) - 0.2 % - - - -
Payout Ratio (TTM) - 47.03 % - - - -
Growth
ATXI NVO REGN VRTX MRNA SGEN
Asset Growth -72.97 % 30.35 % 13.23 % 25.23 % -28.74 % -1.21 %
Gross Profit Growth - 32.32 % 6.49 % 9.25 % -85.12 % 22.93 %
Revenue Growth - 31.26 % 7.76 % 10.17 % -64.94 % 24.65 %
Revenue 3 Year - 90.51 % 55.67 % 59.87 % 2356.27 % 91.84 %
Revenue 5 Year - 124.2 % 110.3 % 218.58 % 1070.62 % 215.48 %
Revenue 10 Year - 66.11 % 549.62 % 608.27 % 6447.35 % 494.04 %
EBIT Growth -80.78 % 37.11 % -14.6 % -12.94 % -145 % 10.13 %
Net Income Growth -606.69 % 50.71 % -8.87 % 8.96 % -156.37 % 9.51 %
Net Income 3 Yeari Growth Per Share -1488.92 % 106.79 % 13.48 % 34.59 % -529.9 % -764.83 %
Net Income 5 Yeari Growth Per Share -135.71 % 133.86 % 74.02 % 70.33 % -160.17 % -276.93 %
Net Income 10 Yeari Growth Per Share -681.91 % 98.61 % 871.12 % 809.6 % -2046.03 % -624.16 %
Operating Income Growth -80.78 % 37.11 % -14.6 % -12.94 % -145 % 10.13 %
Operating Cash Flow Growth (CFG) -24.42 % 38.06 % -8.39 % -14.35 % -162.6 % 9.07 %
Operating 3 Year CFG -1496.46 % 118.29 % 76.95 % 9.63 % -253.56 % -148.34 %
Operating 5 Year CFG -150.78 % 163.51 % 125.17 % 174.78 % -100.11 % -195.86 %
Operating 10 Year CFG -4058.21 % 150.92 % 713.56 % 5187.08 % -4698.89 % -2622.09 %
EPS Growth -7917.02 % 52.28 % -8.54 % 8.33 % -158.15 % 10.81 %
EPS Diluted Growth -7917.02 % 52.37 % -9.03 % 8.35 % -161.39 % 10.81 %
Book Value Per Share 526.86 % 29 % 15.03 % 25.58 % -25.28 % -9.83 %
Share Holder 3 Year Equity Growth Per Share 422.57 % 75.22 % 137.56 % 104.06 % 439.94 % 33.92 %
Share Holder 5 Year Equity Growth Per Share 1311.86 % 121.9 % 219.1 % 291.14 % 92.24 % 220.81 %
Share Holder 10 Year Equity Growth Per Share 221.32 % 49.62 % 1286.9 % 1030.79 % 1519.81 % 691.19 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - - - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth - 4.74 % 0.06 % 44.1 % 3.58 % -23.28 %
Free Cash Flow Growth -63.92 % 9.17 % -17.11 % -16.47 % -183.5 % 3.67 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022
Profitability
ATXI NVO REGN VRTX MRNA SGEN
Gross Profit Margin TTM - 84.65 % 87.16 % 87.21 % 22.46 % 75.4 %
Return on Assets TTM -624.32 % 29.87 % 11.22 % 15.92 % -35.67 % -20.64 %
Return on Equity TTM 521.68 % 91.82 % 15.15 % 22.62 % -41.83 % -28.06 %
Return on Capital Employed TTM -2223.09 % 82.5 % 12.53 % 19.82 % -35.81 % -29.5 %
Net Income Per EBT TTM 110.26 % 79.81 % 95.44 % 82.64 % 124.28 % 101.53 %
EBT Per Ebit TTM 72.05 % 101.7 % 104.74 % 115.19 % 93.44 % 93.47 %
EBIT Per Revenue TTM - 45.03 % 29.46 % 38.53 % -99.69 % -34.37 %
Cash Flow To Debt Ratio TTM - 346.88 % 238.94 % 437.57 % -228.01 % -475.96 %
Receivables Turnover TTM - 3.87 2.51 6.31 37.63 3.64
Payables Turnover TTM - 2.88 2.51 3.46 21.84 2.52
Inventory Turnover TTM - 1.12 0.62 1.71 13.55 1.07
Fixed Asset Turnover TTM - 248.64 % 310.02 % 679.28 % 186.78 % 471.71 %
Asset Turnover TTM - 81.71 % 38.12 % 43.42 % 30.81 % 63.3 %
Operating Cash Flow Per Share TTM -0.37 20.95 43.96 13.73 -7.54 -2.87
Free Cash Flow Per Share TTM -0.37 11.28 36.87 12.72 -9.61 -3.73
Cash Per Share TTM 6.97 % 208.61 % 9758.35 % 4354.48 % 2231.15 % 657.5 %
Operating Cash Flow Sales Ratio TTM - 38.24 % 36.17 % 35.84 % -55.91 % -23.48 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 53.85 % 83.87 % 92.69 % 127.41 % 129.82 %
Cash Flow Coverage Ratios TTM - 346.88 % 238.94 % 437.57 % -228.01 % -475.96 %
Price To Free Cash Flows Ratio TTM -0.3 78.04 26.09 31.6 -13.03 -61.54
Price To Operating Cash Flows Ratio TTM -12.95 40.71 21.77 29.22 -16.57 -79.67
Price Cash Flow Ratio TTM -12.95 40.71 21.77 29.22 -16.57 -79.67
Income Statement (TTM)
ATXI NVO REGN VRTX MRNA SGEN
Revenue $0B $232.26B $13.12B $9.84B $6.75B $1.96B
Gross Profit $0B $196.5B $11.3B $8.58B $2.06B $1.55B
Gross Profit Ratio 0% 84.6% 86.16% 87.17% 30.52% 79.1%
EBITDA $-0.01B $112.94B $5.13B $3.93B $-3.21B $-0.62B
Net Income $-0.01B $83.68B $3.95B $3.62B $-4.71B $-0.61B
EPS Diluted -73.48 18.62 34.77 13.89 -12.34 -3.3
Balance Sheet (MRQ)
ATXI NVO REGN VRTX MRNA SGEN
Long Term Debt $0B $20.53B $2.7B $0.72B $1.22B $0.04B
Total Liabilities $0B $207.93B $7.11B $5.15B $4.57B $0.87B
Total Equity $0B $106.56B $25.97B $17.58B $13.85B $2.8B
Total Investments $0B $17.5B $13.51B $3.45B $4.68B $1.42B
Total Debt $0B $27.01B $2.7B $0.81B $1.24B $0.04B
Total Assets $0B $314.49B $33.08B $22.73B $18.43B $3.67B
Cash Flow Statement (TTM)
ATXI NVO REGN VRTX MRNA SGEN
Net Income $-0.01B $83.68B $3.95B $3.62B $-4.71B $-0.61B
Inventory $0B $-7.42B $-0.27B $-0.32B $0.75B $-0.23B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $108.91B $4.59B $3.54B $-3.12B $-0.45B
Capital Expenditure $-0B $-38.9B $-0.93B $-0.26B $-0.71B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.12
ABCL AbCellera Biologics Inc. 4.03
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.6
ABIO ARCA biopharma, Inc. 3.26
ABOS Acumen Pharmaceuticals, Inc. 3.49
ABSI Absci Corporation 5.08
ABUS Arbutus Biopharma Corporation 2.71
ABVC ABVC BioPharma, Inc. 1.08
ABVX Abivax SA American Depositary Shares 14.54
ACAD ACADIA Pharmaceuticals Inc. 17.05
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.45
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.8037
ACHV Achieve Life Sciences, Inc. 4.735
ACIU AC Immune SA 2.39
ACLX Arcellx, Inc. 52.69
ACRV Acrivon Therapeutics, Inc. Common Stock 9.59
ACST Acasti Pharma Inc. 2.96
ETFs With Exposure to ATXI
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 112.47
VXF Vanguard Extended Market Index Fund 0 168.48
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 127.82
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 127.82
VEMPX Vanguard Extended Market Index InstlPlus 0 315.43
Unlock